| Active ingredients | Dosage form | Quantity of active ingredients | Shortage status | Availability | Reason | Last updated |
| oxytocin | Injection, solution | 10 IU/mL | Discontinued | Reduction in supply until supply is exhausted | Unexpected increase in consumer demand | 24/04/2025 |
| oxytocin | Injection, solution | 5 IU/mL | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 24/04/2025 |
| clonazepam | Oral Liquid, solution | 2.5 mg/mL | Current | Limited Availability | Manufacturing | 24/04/2025 |
| indapamide hemihydrate | Tablet, modified release | 1.5 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 24/04/2025 |
| pentetic acid | Injection, powder for | 5 mg | Current | Unavailable | Manufacturing | 24/04/2025 |
| sodium pyrophosphate | Injection, powder for | 30 mg | Current | Unavailable | Manufacturing | 24/04/2025 |
| medronic acid | Injection, powder for | 10 mg | Current | Unavailable | Manufacturing | 24/04/2025 |
| sodium fluoride | Injection, concentrated | 1 mg/mL | Current | Unavailable | Manufacturing | 24/04/2025 |
| trimethoprim~sulfamethoxazole | Tablet | 160 mg~800 mg | Current | Limited Availability | Unexpected increase in consumer demand | 24/04/2025 |
| oxytocin | Injection, solution | 10 IU | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 24/04/2025 |
| bisoprolol fumarate | Tablet | 2.5 mg | Resolved | Available | Manufacturing | 24/04/2025 |
| clopidogrel hydrogen sulfate | Tablet, film coated | 97.9 mg | Anticipated | Available | Manufacturing | 24/04/2025 |
| montelukast sodium | Tablet, chewable | 5.2 mg | Anticipated | Available | Unexpected increase in consumer demand | 24/04/2025 |
| azithromycin dihydrate | Tablet, film coated | 524.05 mg | Current | Unavailable | Manufacturing | 24/04/2025 |
| naproxen | Oral Liquid, suspension | 25 mg/mL | Current | Limited Availability | Manufacturing | 24/04/2025 |
| trandolapril | Capsule, hard | 1 mg | Current | Unavailable | Manufacturing | 24/04/2025 |
| trandolapril | Capsule, hard | 2 mg | Current | Unavailable | Manufacturing | 24/04/2025 |
| trandolapril | Capsule, hard | 4 mg | Current | Unavailable | Manufacturing | 24/04/2025 |
| quetiapine fumarate | Tablet, modified release | 345.39 mg | Anticipated | Available | Unexpected increase in consumer demand | 24/04/2025 |
| oxytocin | Injection, solution | 5 IU/mL | Current | Limited Availability | Unexpected increase in consumer demand | 24/04/2025 |
| oxytocin | Injection, solution | 10 IU/mL | Anticipated | Available | Manufacturing | 24/04/2025 |
| celecoxib | Capsule, hard | 100 mg | Resolved | Available | Manufacturing | 24/04/2025 |
| escitalopram oxalate | Tablet, film coated | 25.47 mg | Resolved | Available | Manufacturing | 24/04/2025 |
| bosentan monohydrate | Tablet, film coated | 129.08 mg | Current | Unavailable | Transport / Logistic issues / Storage capacity issues | 24/04/2025 |
| betahistine dihydrochloride | Tablet | 16 mg | Resolved | Available | Manufacturing | 24/04/2025 |
| tadalafil | Tablet, film coated | 10 mg | Resolved | Available | Manufacturing | 24/04/2025 |
| tadalafil | Tablet, film coated | 20 mg | Resolved | Available | Manufacturing | 24/04/2025 |
| metformin hydrochloride | Tablet, film coated | 500 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 24/04/2025 |
| busulfan | Injection, concentrated | 60 mg | Current | Limited Availability | Manufacturing | 24/04/2025 |
| risperidone | Tablet, film coated | 3 mg | Current | Unavailable | Transport / Logistic issues / Storage capacity issues | 24/04/2025 |
| nebivolol hydrochloride | Tablet | 5.45 mg | Current | Unavailable | Manufacturing | 24/04/2025 |
| tamoxifen citrate | Tablet | 30.34 mg | Current | Limited Availability | Manufacturing | 24/04/2025 |
| sitagliptin hydrochloride monohydrate | Tablet, film coated | 56.69 mg | Current | Unavailable | Manufacturing | 24/04/2025 |
| sildenafil citrate | Tablet, film coated | 70.24 mg | Current | Unavailable | Unexpected increase in consumer demand | 24/04/2025 |
| melatonin | Capsule, hard | 3 mg | Resolved | Available | Unexpected increase in consumer demand | 24/04/2025 |
| cabergoline | Tablet, uncoated | 1 mg | Anticipated | Available | Manufacturing | 24/04/2025 |
| balsalazide sodium | Capsule | 750 mg | Resolved | Available | Manufacturing | 24/04/2025 |
| gefitinib | Tablet, film coated | 250 mg | Resolved | Available | Commercial Changes / Commercial viability | 24/04/2025 |
| methylphenidate hydrochloride | Tablet, uncoated | 10 mg | Current | Limited Availability | Transport / Logistic issues / Storage capacity issues | 23/04/2025 |
| fentanyl | Drug delivery system, transdermal | 4.2 mg | Discontinued | Unavailable | Manufacturing | 23/04/2025 |
| fentanyl | Drug delivery system, transdermal | 8.4 mg | Discontinued | Unavailable | Manufacturing | 23/04/2025 |
| fentanyl | Drug delivery system, transdermal | 12.6 mg | Discontinued | Unavailable | Manufacturing | 23/04/2025 |
| fentanyl | Drug delivery system, transdermal | 16.8 mg | Discontinued | Unavailable | Manufacturing | 23/04/2025 |
| bupivacaine hydrochloride monohydrate | Injection, solution | 52.7 mg | Current | Limited Availability | Unexpected increase in consumer demand | 23/04/2025 |
| fentanyl | Drug delivery system, transdermal | 2.1 mg | Discontinued | Unavailable | Manufacturing | 23/04/2025 |
| benzathine benzylpenicillin tetrahydrate | Injection, suspension | 1200000 USP Unit | Current | Limited Availability | Manufacturing | 23/04/2025 |
| amiodarone hydrochloride | Injection, solution | 150 mg | Anticipated | Available | Unexpected increase in demand due to other sponsors unable to supply | 23/04/2025 |
| methylphenidate hydrochloride | Capsule, modified release | 10 mg | Anticipated | Available | Manufacturing | 23/04/2025 |
| pramipexole dihydrochloride monohydrate | Tablet | .125 mg | Anticipated | Available | Manufacturing | 23/04/2025 |
| risedronate sodium hemipentahydrate | Tablet, film coated | 173.4 mg | Anticipated | Available | Manufacturing | 23/04/2025 |
| montelukast sodium | Tablet, chewable | 5.2 mg | Resolved | Available | Manufacturing | 23/04/2025 |
| montelukast sodium | Tablet, film coated | 10.4 mg | Anticipated | Available | Manufacturing | 23/04/2025 |
| montelukast sodium | Tablet, film coated | 10.4 mg | Anticipated | Available | Manufacturing | 23/04/2025 |
| isotretinoin | Capsule, soft | 10 mg | Current | Unavailable | Manufacturing | 23/04/2025 |
| propofol | Injection, emulsion | 10 g/L | Current | Limited Availability | Transport / Logistic issues / Storage capacity issues | 23/04/2025 |
| candesartan cilexetil | Tablet, uncoated | 16 mg | Anticipated | Available | Manufacturing | 23/04/2025 |
| raloxifene hydrochloride | Tablet, film coated | 60 mg | Current | Unavailable | Unexpected increase in consumer demand | 23/04/2025 |
| estradiol~dydrogesterone | Tablet, film coated | 1 mg~10 mg | Current | Limited Availability | Manufacturing | 23/04/2025 |
| acarbose | Tablet | 100 mg | Anticipated | Available | Manufacturing | 23/04/2025 |
| flecainide acetate | Tablet, uncoated | 100 mg | Current | Limited Availability | Manufacturing | 23/04/2025 |
| methylphenidate hydrochloride | Capsule, modified release | 60 mg | Anticipated | Available | Manufacturing | 23/04/2025 |
| noradrenaline (norepinephrine) acid tartrate monohydrate | Injection, concentrated | 2 mg/mL | Anticipated | Available | Transport / Logistic issues / Storage capacity issues | 23/04/2025 |
| teriflunomide | Tablet, film coated | 14 mg | Current | Limited Availability | Manufacturing | 23/04/2025 |
| olanzapine | Tablet, uncoated | 5 mg | Current | Limited Availability | Manufacturing | 23/04/2025 |
| montelukast sodium | Tablet, chewable | 5.2 mg | Current | Unavailable | Manufacturing | 23/04/2025 |
| methylphenidate hydrochloride | Capsule, hard | 40 mg | Anticipated | Available | Unexpected increase in demand due to other sponsors unable to supply | 23/04/2025 |
| methylphenidate hydrochloride | Capsule, hard | 20 mg | Anticipated | Available | Unexpected increase in demand due to other sponsors unable to supply | 23/04/2025 |
| methylphenidate hydrochloride | Capsule, hard | 30 mg | Anticipated | Available | Unexpected increase in demand due to other sponsors unable to supply | 23/04/2025 |
| methylphenidate hydrochloride | Capsule, hard | 10 mg | Anticipated | Available | Unexpected increase in demand due to other sponsors unable to supply | 23/04/2025 |
| methylphenidate hydrochloride | Capsule, hard | 60 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 23/04/2025 |
| bicisate dihydrochloride | Injection, powder for | .9 mg | Resolved | Available | Manufacturing | 23/04/2025 |
| estradiol hemihydrate | Tablet, film coated | 2.06 mg | Resolved | Available | Manufacturing | 23/04/2025 |
| methylphenidate hydrochloride | Capsule, modified release | 20 mg | Anticipated | Available | Manufacturing | 23/04/2025 |
| methylphenidate hydrochloride | Capsule, modified release | 30 mg | Anticipated | Available | Manufacturing | 23/04/2025 |
| methylphenidate hydrochloride | Capsule, modified release | 40 mg | Anticipated | Available | Manufacturing | 23/04/2025 |
| gentamicin | Injection, solution | 80 mg | Current | Unavailable | Manufacturing | 22/04/2025 |
| acetylcysteine | Injection, concentrated | 2 g | Resolved | Available | Manufacturing | 22/04/2025 |
| fentanyl | Drug delivery system, transdermal | 16.8 mg | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 22/04/2025 |
| azithromycin dihydrate | Tablet, film coated | 524.1 mg | Resolved | Available | Unexpected increase in demand due to other sponsors unable to supply | 22/04/2025 |
| vincristine sulfate | Injection, solution | 1 mg/mL | Anticipated | Available | Manufacturing | 22/04/2025 |
| bisoprolol fumarate | Tablet | 10 mg | Resolved | Available | Manufacturing | 22/04/2025 |
| valsartan~hydrochlorothiazide | Tablet, film coated | 320 mg~25 mg | Current | Limited Availability | Manufacturing | 22/04/2025 |
| sildenafil citrate | Tablet, film coated | 28.1 mg | Resolved | Available | Manufacturing | 22/04/2025 |
| risperidone | Tablet, film coated | 1 mg | Resolved | Available | Unexpected increase in consumer demand | 22/04/2025 |
| capecitabine | Tablet, film coated | 500 mg | Current | Unavailable | Manufacturing | 22/04/2025 |
| ezetimibe~rosuvastatin calcium | Tablet~Tablet, film coated | 10 mg~41.583 mg | Current | Limited Availability | Manufacturing | 22/04/2025 |
| ezetimibe~rosuvastatin calcium | Tablet~Tablet, film coated | 10 mg~5.198 mg | Resolved | Available | Manufacturing | 22/04/2025 |
| capecitabine | Tablet, film coated | 500 mg | Current | Limited Availability | Unexpected increase in consumer demand | 22/04/2025 |
| clonidine hydrochloride | Tablet | 100 microgram | Current | Unavailable | Unexpected increase in consumer demand | 22/04/2025 |
| hydrocortisone | Tablet, uncoated | 20 mg | Current | Limited Availability | Manufacturing | 22/04/2025 |
| hydrocortisone | Tablet, uncoated | 20 mg | Current | Limited Availability | Manufacturing | 22/04/2025 |
| avibactam sodium~ceftazidime pentahydrate | Injection, powder for | 543.5 mg~2329.7 mg | Anticipated | Available | Unexpected increase in consumer demand | 22/04/2025 |
| carmustine~ethanol absolute | Diluent, not applicable~Injection, powder for | 100 mg~3 mL | Resolved | Available | Unexpected increase in demand due to other sponsors unable to supply | 22/04/2025 |
| daptomycin | Injection, powder for | 500 mg | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 22/04/2025 |
| daptomycin | Inhalation, powder for | 350 mg | Current | Unavailable | Manufacturing | 22/04/2025 |
| levothyroxine sodium | Tablet | 75 microgram | Current | Unavailable | Manufacturing | 22/04/2025 |
| lorazepam | Tablet | 2.5 mg | Resolved | Available | Manufacturing | 22/04/2025 |
| gentamicin sulfate | Injection, solution | 135.6 mg | Resolved | Available | Unexpected increase in demand due to other sponsors unable to supply | 22/04/2025 |
| cytarabine | Injection, solution | 100 mg/mL | Anticipated | Available | Manufacturing | 22/04/2025 |
| estradiol~norethisterone acetate | Drug delivery system, transdermal | .512 mg~4.8 mg | Current | Unavailable | Manufacturing | 22/04/2025 |
| hydrochlorothiazide~quinapril hydrochloride | Tablet, film coated | 12.5 mg~10.832 mg | Current | Unavailable | Manufacturing | 22/04/2025 |
| quinapril hydrochloride~hydrochlorothiazide | Tablet, film coated | 21.664 mg~12.5 mg | Current | Unavailable | Manufacturing | 22/04/2025 |
2025年4月27日